Anil Kumar Jaiswal

Anil Kumar Jaiswal

Auto-generated profile, based on publicly available information

Anil Kumar Jaiswal

Parasitology Division, CSIR-Central Drug Research Institute, Lucknow 226031, India

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
SAShalini Asthana
Shalini Asthana
AJAnil K. Jaiswal
Anil K. Jaiswal
PGPramod K. Gupta
Pramod K. Gupta
VPVivek K. Pawar
Vivek K. Pawar
ADAnuradha Dube
Anuradha Dube
MKManish K. Kedar
Manish K. Kedar
The accessible treatment options for life-threatening neglected visceral leishmaniasis (VL) disease have problems with efficacy, stability, adverse effects, and cost, making treatment a complex issue. Here we formulated nanometric amphotericin B (AmB)-encapsulated chitosan nanocapsules (CNC-AmB) using a polymer deposition technique mediated by nanoemulsion template fabrication. CNC-AmB exhibited good steric stabilityin vitro, where the chitosan content was found to be efficient at preventing destabilization in the presence of protein and Ca2+. A toxicity study on the model cell line J774A and erythrocytes revealed that CNC-AmB was less toxic than commercialized AmB formulations such as Fungizone and AmBisome. The results ofin vitro(macrophage-amastigote system; 50% inhibitory concentration [IC50], 0.19 ± 0.04 μg AmB/ml) andin vivo(Leishmania donovani-infected hamsters; 86.1% ± 2.08% parasite inhibition) experiments in conjunction with effective internalization by macrophages illustrated the efficacy of CNC-AmB at augmenting antileishmanial properties. Quantitative mRNA analysis by real-time PCR (RT-PCR) showed that the improved effect was synergized with the upregulation of tumor necrosis factor alpha (TNF-α), interleukin-12 (IL-12), and inducible nitric oxide synthase and with the downregulation of transforming growth factor β (TGF-β), IL-10, and IL-4. These research findings suggest that a cost-effective CNC-AmB immunoadjuvant chemotherapeutic delivery system could be a viable alternative to the current high-cost commercial lipid-based formulations.

9 August 2014 in Applied Biochemistry and Biotechnology
Verified
Journal Article
Closed access
PDF file
VJVineet Jain
Vineet Jain
AGAnnie Gupta
Annie Gupta
VPVivek K. Pawar
Vivek K. Pawar
SAShalini Asthana
Shalini Asthana
AJAnil K. Jaiswal
Anil K. Jaiswal
MKManish K. Kedar
Manish K. Kedar

1 December 2017 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
PSPankaj Kumar Singh
Pankaj Kumar Singh
VPVivek K. Pawar
Vivek K. Pawar
AJAnil K. Jaiswal
Anil K. Jaiswal
YSYuvraj Singh
Yuvraj Singh
CSCheruvu Hanumanth Srikanth
Cheruvu Hanumanth Srikanth
MKManish K. Kedar
Manish K. Kedar



12 June 2009 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
NSNasib Singh
Nasib Singh
RGReema Gupta
Reema Gupta
AJAnil K. Jaiswal
Anil K. Jaiswal
SSShyam Sundar
Shyam Sundar
ADAnuradha Dube
Anuradha Dube
Several Leishmania strains with episomal expression of green fluorescent protein (GFP) require constant drug pressure for its continuous expression and hence limit its use in ex vivo or in vivo systems. The aim of this study was to alleviate this problem by stably integrating the GFP gene into the parasite genome, so as to use these transfectants for ex vivo and in vivo drug screening. The GFP gene was integrated downstream of the 18S ribosomal promoter region of Leishmania donovani. After initial selection, GFP-expressing parasites—both sodium stibogluconate (SAG)-susceptible (2001) and -resistant (2039) isolates—were grown without adding G418. The infectivity of these transfectants to macrophages (J774.1) as well as to hamsters was checked. The ex vivo screening assay was standardized using standard antileishmanial drugs. A constitutive and enhanced expression of GFP in promastigote and amastigote stages was achieved for ∼12 months without any need for drug pressure. These transfectants were highly infective to macrophage cell lines as well as to hamsters, as observed by fluorescence microscopy and flow cytometry (FACS). GFP-tagged promastigotes as well as intracellular amastigotes were found to be highly susceptible to miltefosine, amphotericin B and pentamidine, in a concentration-dependent manner. SAG was inactive against the GFP-promastigotes, as well as SAG-resistant intracellular amastigotes, correlating well with earlier reports. The GFP-transfectants were found to be suitable for FACS-based ex vivo screening assays. They were also infective to hamsters up to day 60 post-infection.